<i>ADAM33</i> linkage disequilibrium plot (100·r²) in the Vlagtwedde/Vlaardingen cohort.

<p><i>ADAM33</i> linkage disequilibrium plot (100·r²) in the Vlagtwedde/Vlaardingen cohort.</p

Distribution of genotypes according to all-cause and cause-specific mortality.

*<p>Differences between alive subjects and those who died (excluding external causes of death) tested with χ² test.</p>**<p>Differences between alive subjects and those who died due to COPD tested with χ² test.</p>***<p>Differences between alive subjects and those who died due to CVD tested with χ² test.</p

Risk of all-cause mortality according to gender and smoking habits.

<p><b>Females</b> n = 676 (103 deaths); <b>Males</b> n = 714 (166 deaths); <b>Never smokers</b> n = 445 (62 deaths); <b>Ever smokers</b> n = 945 (207 deaths); n = 14 deaths due to external causes are excluded.</p>*<p>P value <0.05.</p>**<p>P = 0.07.</p

Hazard ratio (95% CI) of all-cause, COPD and cardiovascular mortality.

<p>Cox regression adjusted for gender, age, FEV₁, height, place of residence and packyears smoking (all at the last survey 1989/1990).</p>*<p>Excluding external causes of death.</p>**<p>Primary or secondary causes of death.</p>***<p>P value <0.05.</p

Position of genotyped SNPs in the <i>ADAM33</i> gene and the domain organization of <i>ADAM33</i> (adapted from [10]).

<p>Position of genotyped SNPs in the <i>ADAM33</i> gene and the domain organization of <i>ADAM33</i> (adapted from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0067768#pone.0067768-Gosman1" target="_blank">[10]</a>).</p

Survival curves for all-cause and CVD mortality according to SNP T_2.

<p>Survival curves for all-cause and CVD mortality according to SNP T_2.</p

Characteristics of participants at visit 1989/1990 by vital status on Dec 31^st, 2008.

<p>All variables are expressed as number (%) or mean (SD) or median (range) as appropriate.</p>*<p>Either primary or secondary cause of death, number (% of all deaths).</p>**<p>Suicides, homicides, traffic accidents <i>etc.</i></p

SNPs in the <i>nAChR</i> cluster and annual FEV₁ decline (ml/year) in smokers, ex-smokers and never smokers.

<p>B = regression coefficient from the linear mixed-effect model, adjusted for 1 = quitting smoking, 2 = restarting smoking, 3 = never smoker, gender, height and age at the first of two successive surveys and time between two successive surveys. “Smokers” refer to those paired observations in which the subject was a smoker at the first of two successive surveys and quitted smoking or continued smoking at the nearest follow-up survey. “Ex-smokers” refer to those paired observations in which the subject was an ex-smoker at the first of two successive surveys and continued being an ex-smoker or restarted smoking at the nearest follow-up survey. “Never smoker” refer to those paired observations in which the subject was a never smoker at the first of two successive surveys and continued being a never smoker at the nearest follow-up survey. a = heterozygotes vs. wild-type; b = homozygote variant vs. wild-type.</p

Survival curves for COPD mortality according to SNPs Q_1, S_1, S_2 and T_2.

<p>Survival curves for COPD mortality according to SNPs Q_1, S_1, S_2 and T_2.</p

Summary of the observed associations in the current study.

<p>SNPs = single nucleotide polymorphisms; COPD = Chronic Obstructive Pulmonary Disease; <i>nAChR</i> = <i>nicotinic acetylcholine receptor</i>; + = association; − = no association.</p